Using a mouse model of MASLD, we found that enhancing KISS1R activation by administering a long-acting kisspeptin analog, KPA [45], decreases the synthesis of numerous lipid species shown to be linked to obesity, type 2 diabetes, and steatosis, in addition to HCC [21,22]. The gene discussed is KISS1; the disease is steatosis.